Craft

Alar Pharmaceuticals

Stock Price

NT$169

2024-10-29

Market Capitalization

NT$11.1 B

2024-10-29

Revenue

NT$2.8 M

FY, 2025

Alar Pharmaceuticals Summary

Company Summary

Overview
Alar Pharmaceuticals is a new drug development company. It offers opioid use disorder, chronic pain, major depressive disorder, and other services.
Type
Public
Status
Active
Founded
2016
Website
http://alarpharm.com
Cybersecurity rating
Sectors

Table of Contents

Alar Pharmaceuticals Financials

Summary Financials

Revenue (FY, 2025)
NT$2.8M
Gross profit (FY, 2025)
NT$2.8M
Net income (FY, 2025)
(NT$79.7M)
Cash (FY, 2025)
NT$1.8B
EBIT (FY, 2025)
(NT$167.9M)
Enterprise value
$9.3B

Footer menu